U.S., Jan. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07369739) titled 'Golidocitinib Combined With Selinexor for CAEBVD' on Jan. 03.
Brief Summary: This study is a multicenter, prospective, single-arm clinical investigation, with patients with CAEBVD as the main research subjects, to evaluate the effectiveness of the combined treatment regimen of golidocitinib and selinexor.
Study Start Date: Jan. 01
Study Type: INTERVENTIONAL
Condition:
Lymphohistiocytosis
EBV
CAEBV
Intervention:
DRUG: golidocitinib
golidocitinib 150 mg once daily.
DRUG: Selinexor (combination therapy)
selinexor 40 mg once weekly.
Recruitment Status: RECRUITING
Sponsor: Beijing Friendship Hospital
Information provided by (...